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Extracellular nucleotides are among the most potent
mediators of mucociliary clearance (MCC) in human
lungs. However, clinical trials revealed that aerosolized
nucleotides provide only a transient improvement of
MCC to patients diagnosed with cystic fibrosis (CF). In
this study, we identified the mechanism that eliminates
extracellular nucleotides from human airways. Polar-
ized primary cultures of human bronchial epithelial
cells were impermeable to extracellular nucleotides but
rapidly dephosphorylated ATP into ADP, AMP, and
adenosine. The half-life of a therapeutic ATP concentra-
tion (0.1 mM) was 20 s within the periciliary liquid
layer. The mucosal epithelial surface eliminated P2 re-
ceptor agonists (ATP  UTP > ADP > UDP) at 3-fold
higher rates than the serosal surface. We also showed
that mucosal (not serosal) ectoATPase activity increases
toward areas most susceptible to airway obstruction
(nose < bronchi << bronchioles). Bronchial cultures
from patients with CF, primary ciliary dyskinesia, or
1-antitrypsin deficiency exhibited 3-fold higher muco-
sal (not serosal) ectoATPase activity than normal cul-
tures. Time course experiments indicated that CF en-
hances ATP elimination and adenosine accumulation on
the mucosal surface. Furthermore, nonspecific alkaline
phosphatase was identified as the major regulator of
airway nucleotide concentrations in CF, primary ciliary
dyskinesia, and 1-antitrypsin deficiency. The ectoAT-
Pase activity and mRNA expression of mucosally re-
stricted nonspecific alkaline phosphatase were 3-fold
higher on bronchial cultures from these patients than
from healthy subjects. This study demonstrates that the
duration of nucleotide-mediated MCC is limited by epi-
thelial ectonucleotidases throughout human airways,
with the efficiency of this mechanism enhanced in
chronic inflammatory lung diseases, including CF.
Healthy lungs are protected against bacterial and viral in-
fections by mediators of mucociliary clearance (MCC)1 mecha-
nisms taking place on the epithelium lining the airways. The
mucosal surface is covered by a mucus layer maintained above
the cilia by a PCL layer (1). Infectious particles are trapped in
the mucus and transported upward by coordinated cilia beating
activity. Evidence derived from animal studies and human cell
culture models indicates that ion transport across the epithe-
lium regulates PCL volume (2–4) and that PCL depletion leads
to mucostasis (4). Mutations of the gene encoding the cystic
fibrosis transmembrane regulator (CFTR) epithelial anion
transporter are associated with chronic airway obstruction,
infection, and inflammation in CF patients (5).
Extracellular nucleotides regulate all major components of
MCC on human airway epithelial surfaces. Through G protein-
coupled P2Y receptors, they stimulate Ca2- and PKC-depend-
ent mucin secretion, cilia beating activity, and ion channels
that regulate PCL volume, namely Ca2-activated Cl chan-
nels (6). Two members of the P2Y receptor subfamily were
identified on the mucosal surface of human airway epithelia:
the P2Y2 receptor equally activated by ATP and UTP (not ADP
or UDP) (7) and the P2Y6 receptor potently activated by UDP
and weakly by ADP (8, 9). The serosal surface expresses P2Y2
(10) and P2Y1 (ADP  ATP  UTP) (11) receptors. In addition,
two members of the P2X receptor subfamily were identified by
RT-PCR in cultured human airway epithelia: P2X4 and P2X5
(12). Calcium influx through these ligand-gated cation chan-
nels (ATP  ADP) stimulated Cl secretion (12) and cilia
beating activity (13).
The physiological importance of nucleotide-mediated MCC is
supported by numerous studies showing that airway epithelia
release ATP under basal conditions (14, 15) and in response to
various mechanical stimulations, including membrane stretch
(11, 16), shear stress (17, 18), and hypotonicity-induced swell-
ing (19–21). However, nucleotide-mediated signaling pathways
do not sustain normal PCL volume under resting conditions
because basal ATP levels are insufficient to activate Ca2-
activated Cl channels (22). On the other hand, resting airway
epithelia exhibit extracellular adenosine concentrations suffi-
cient to activate CFTR (23). Adenosine binds to G protein-
coupled A2B receptors and mediates cAMP-dependent (24)
stimulation of cilia beating (25, 26) and ion transport (23,
27–29).
Cystic fibrosis patients are unable to maintain normal PCL
volume using the adenosine receptor-CFTR pathway and
therefore depend on mechanically-stimulated ATP release (i.e.
coughing, wheezing, and clapping) for Ca2-activated Cl
channels activation. However, clinical studies indicated that
nucleotides provide only a short-term improvement of MCC in
CF patients (30). Aerosolized UTP, in conjunction with amilo-
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ride (sodium channel blocker), increased MCC to normal levels
in 20 min in CF patients (31, 32). In polarized cultures of CF
nasal epithelial cells, UTP restored normal PCL volume in 1
h (4). The transient nature of these responses suggests that
nucleotide concentrations above resting levels are rapidly elim-
inated from human airway epithelial surfaces.
Given the importance of P2 receptor-mediated MCC for CF
patients, we investigated the mechanisms of nucleotide clear-
ance from human airway epithelial surfaces under normal and
pathological conditions. We tested whether they are eliminated
by paracellular permeation through the epithelial layer and/or
cell surface metabolism. We also describe, for the first time, the
polarity and distribution of these ectonucleotidase activities
throughout human airways with epithelial cultures of nasal,
bronchial, and bronchiolar cells. The impact of chronic inflam-
matory lung diseases on nucleotide clearance was examined
with epithelial cultures from patients diagnosed with CF, PCD,
or AT. Finally, we addressed the identity of the proteins
responsible for nucleotide metabolism. Three families of ecto-
nucleotidases have been identified on mammalian cells: ecto-
nucleotide pyrophosphatase/phosphodiesterases, alkaline
phosphatases (AP), and ectonucleoside triphosphate diphos-
phohydrolases (33). We recently demonstrated the presence of
NS AP on the mucosal surface of human airway epithelia (34).
Because NS AP expression was up-regulated by the major
airway pro-inflammatory cytokine, interleukin-1 (34), we
tested the impact of CF, PCD, and AT on the activity and
expression of NS AP. This study demonstrates that P2 receptor
agonists are rapidly eliminated from human airway epithelial
surfaces by ectonucleotidases, including NS AP. Furthermore,
we show that nucleotide clearance is accelerated in CF by
mechanisms that involve chronic inflammation.
EXPERIMENTAL PROCEDURES
Cell Culture—Polarized cultures of human airway epithelial cells
from healthy donors and patients with CF, PCD, or AT were grown as
previously described (35). In brief, the cells were isolated by protease
digestion (36) and plated on porous Transwell Col filters (well diameter,
12 mm; pore size, 0.45 M) in air-liquid interface medium (50:50 mix-
ture of LHC Basal and Dulbecco’s modified Eagle’s medium-H, 0.5
ng/ml epithelial growth factor, 50 nM retinoic acid, 0.5 mg/ml bovine
serum albumin, 0.8% bovine pituitary extract, 50 units/ml penicillin,
and 50 g/l streptomycin) (37). The confluent cultures were main-
tained in air-liquid interface with medium added only to the serosal
compartment. Passage 1 (P1) cultures were obtained by plating the
digested cells on a collagen-coated tissue culture dish (5–10 days) in
LHC9 medium (36) containing 25 ng/ml epithelial growth factor, 50 nM
retinoic acid, 40 g/ml gentamicin, 0.5 mg/ml bovine serum albumin,
0.8% bovine pituitary extract, 50 units/ml penicillin, 50 g/l strepto-
mycin, and 0.125 mg/ml amphotericin. Once they reached confluence,
the cells were trypsinized and subpassaged on porous Transwell Col
filters. After 4 weeks, primary and P1 cultures were composed of co-
lumnar ciliated cells (90%) and secretory cells covering a layer of
basal-like cells (38). Experiments were conducted on cultures of tran-
sepithelial electrical resistance 300 /cm2. Lactate dehydrogenase
activity was employed as a test of cellular integrity.
Ectonucleotidase Assays—Epithelial cultures were washed three
times with phosphate-buffered saline (PBS) and once with Krebs buffer
(KRB) (in mM): 140 Na, 120 Cl, 5.2 K, 25 HCO3
, 2.4 HPO4
, 1.6
Ca2, 1.6 Mg2, 5.2 glucose, and 25 HEPES (pH 7.4) and then prein-
cubated in KRB (0.35 ml of mucosal/serosal) for 30 min at 37 °C (5%
CO2/95% O2). All reactions were initiated by the addition of the sub-
strate (dissolved (10) in 0.035 ml of KRB) to the mucosal and/or
serosal buffer and stopped by transferring 10-l aliquots to tubes con-
taining 0.3 ml of ice-cold water. The samples were boiled 5 min, filtered,
and analyzed by reversed-phase paired-ion HPLC.
PCL Layer Assays—Primary cultures of human bronchial epithelial
cells were assayed for the metabolism of 0.1 mM ATP within the PCL, as
previously described (4). In brief, several wells of the same culture were
washed three times with PBS and preincubated for 60 min to restore
normal PCL height. The substrate was prepared by suspending 0.1 mg
of ATP and 3 Ci (3 l) of [3H]ATP into 0.2 ml of perfluorocarbon
(FC-72). The mixture was sonicated for 10 min, and 10 l was added to
the mucosal surface of each well. Perfluorocarbon evaporates in sec-
onds, leaving the substrate within the PCL layer. The reactions were
ended at different time intervals by washing the epithelial surface with
PBS (0.3 ml) and transferring the entire volume to a tube containing 40
l of 50 mM EDTA. The samples were boiled for 3 min, filtered, and
analyzed by HPLC.
Synthesis of [3H]ADP and [3H]UDP—Tritiated ADP was obtained
from [3H]ATP by an hexokinase reaction, as described previously (8). In
brief, 50 Ci of [3H]ATP were incubated with 10 units/ml hexokinase
(30 min, 37 °C) in 0.2 ml of KRB. The samples were boiled for 3 min to
eliminate the hexokinase activity, and full conversion of [3H]ATP into
[3H]ADP was confirmed by HPLC.
Enzyme Release Assays—Mucosal epithelial surfaces were washed
three times with PBS and once with KRB and then incubated in bilat-
eral KRB (350 l of mucosal/serosal) for 0, 30, or 60 min at 37 °C (5%
CO2/95% O2). The conditioned buffer was collected, centrifuged at
14,000  g (4 °C; 20 min) to remove detached cells and debris. Released
ATPase activity was measured by transferring 315 l to a tube contain-
ing 1 mM ATP in 35 l of KRB (37 °C) and collecting aliquots over time
for HPLC analysis. These rates of ATP hydrolysis were compared with
measurements performed the next day on the mucosal surface of the
same wells to determine the contribution of released enzyme to total
surface activity.
HPLC Separation of Nucleotides—The separation system consisted
of a Dinamax C-18 column and a mobile phase developed with buffer A
(10 mM KH2PO4 and 8 mM tetrabutyl ammonium hydrogen sulfate
(TBASH), pH 5.3) from 0–10 min, buffer B (100 mM KH2PO4, 8 mM
TBASH, and 10% MeOH, pH 5.3) from 10–20 min, and buffer A from
20–30 min. Absorbance was monitored at 254 nm with an online Model
490 multiwavelength detector (Shimadzu Scientific Instruments, Inc.,
Columbia, MD), and radioactivity was determined online with a Flo-
One radiomatic detector (Packard, Canberra, Australia) as described
previously (39).
RNase Protection Assays—Total RNA and RNase protection assay
probes for NS AP were prepared as previously described (34). In brief,
total RNA was extracted from primary cultures of human bronchial
epithelial cells and amplified by RT-PCR with primers generated from
the sequence of human NS AP. The [32P]CTP-labeled RPA probes were
prepared from plasmids containing the NS AP cDNA. The probes were
purified by electrophoresis, eluted, and hybridized with 20 g of total
RNA (RPA III kit; Ambion). The protected fragments were separated by
electrophoresis and the gels dried on a vacuum dryer (60 °C, 4 h) and
exposed to a storage phosphor screen (Amersham Biosciences). The
screen was scanned with an optical scanner (Storm; Amersham Bio-
sciences) and the signals quantified by digital image-analyzing software
(ImageQuant; Amersham Biosciences). Sense strand and yeast RNA
controls yielded no signal on the gels.
Materials—All 5-nucleotides and adenosine were purchased from
Roche Applied Science. KH2PO4, tetrabutyl ammonium hydrogen sul-
fate, and HEPES were obtained from Sigma and perfluorocarbon (FC-
72) from 3 M (St. Paul, MN). HPLC-grade water was bought from
Fisher Scientific (Pittsburgh, PA). Cell culture media, bovine serum
albumin, bovine pituitary extract, epithelial growth factor, gentamicin,
penicillin, retinoic acid, and streptomycin were bought from Invitrogen.
[2,83H]ATP (40–50 Ci/mmol) and [2,83H]UTP (40–50 Ci/mmol) were
from Amersham Biosciences. Salts and solvents were of analytical
grade.
Data Analysis—Enzyme assays and RNase protection assays were
conducted on polarized cultures of airway epithelial cells from at least
three healthy donors or three patients diagnosed with CF, PCD, or AT,
unless stated otherwise. Nucleotide metabolism was calculated from
the initial linear rate of substrate decay monitored by HPLC and
presented as nmolesmin1cm2. Values were expressed as means 	
S.E. of the mean. Unpaired Student’s t tests were used to assess the
significance between two independent data sets. Paired t tests were
used for comparisons between mucosal and serosal surfaces of the same
culture or between conditioned buffer and the corresponding mucosal
surface. All linear regressions, curve fits, and data transformations
were performed with PC computer programs Excel, Origin, and Sigma
plot.
RESULTS
Mechanism of Nucleotide Clearance—We first determined
whether extracellular nucleotides are eliminated from human
airways by permeation through the epithelial layer and/or by
cell surface metabolism. The P2 receptor agonist 0.1 mM
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[3H]ADP was added to the mucosal surface of bronchial cul-
tures, and buffer samples collected through time were analyzed
by HPLC. Fig. 1A indicates that no radiolabeled compound
accumulated in the serosal compartment over 60 min, except
for traces of [3H]hypoxanthine. Similar results were obtained
with 0.1 mM [3H]ATP added to the mucosal surface of human
bronchial cultures (34). Furthermore, reciprocal experiments
conducted with 0.1 mM [3H]ADP added to the serosal surface
showed that all radiolabeled compounds were confined to the
serosal compartment (Fig. 1B). Taken together, these experi-
ments demonstrate that nucleotide clearance in human air-
ways does not involve permeation through the epithelial layer.
These experiments also showed that less phosphorylated
nucleotides accumulated on the epithelial surface exposed to
[3H]ADP (Fig. 1, A and B), suggesting that P2 receptor agonists
may be eliminated by cell surface metabolism. To test this
hypothesis, the mucosal surface of bronchial cultures was in-
cubated with 0.1 mM [3H]ATP or [3H]UTP in KRB, and buffer
samples collected over 5 min were analyzed by HPLC. Fig. 2A
shows that [3H]ATP gradually disappeared and [3H]ADP,
[3H]AMP, [3H]adenosine, and [3H]inosine accumulated. Like-
wise, the epithelial surface eliminated [3H]UTP by a mecha-
nism that generated [3H]UDP, [3H]UMP, and [3H]uridine. The
inhibition of concentrative (2 mM phloridzin) (40) and equili-
brative (100 M dipyridamole) (41) nucleoside/nucleobase
transporters accelerated the accumulation of [3H]adenosine,
[3H]inosine, and [3H]hypoxanthine from [3H]ATP and of [3H]u-
ridine from [3H]UTP (Fig. 2B), supporting their cell surface
production. Accordingly, total radioactivity measured after 5
min corresponded to 90% of initial [3H]ATP or [3H]UTP
counts (Fig. 2A). Collectively, these results suggest that P2
receptor agonists are eliminated from human airway epithelia
by cell surface dephosphorylation.
Mucosal and Serosal Surfaces: Two Distinct Compart-
ments—The permeability experiments suggested that extracel-
lular nucleotide metabolism occurs on both mucosal (Fig. 1A)
and serosal (Fig. 1B) surfaces of human airway epithelia. We
therefore investigated whether the distinct nucleotide and nu-
cleoside compositions reported for mucosal (adenosine 
AMP  ADP  ATP) and serosal (ADP 
 AMP  adenosine
[tmt] ATP) surfaces (42) may reflect local differences in cell
surface metabolism. Time course experiments showed that 0.1
mM [3H]ATP, [3H]ADP, and [3H]AMP are all sequentially de-
phosphorylated on both epithelial surfaces (Fig. 3). However,
all three nucleotides were eliminated at 3-fold higher rates on
the mucosal surface. Furthermore, mucosal and serosal profiles
for [3H]ATP metabolism differed with respect to [3H]ADP and
[3H]adenosine production. On the mucosal surface, [3H]ATP
dephosphorylation resulted in a transient production of
[3H]ADP and a sustained accumulation of [3H]adenosine. The
nucleoside represented more than 80% of total reaction prod-
ucts by the end of the incubation period. On the serosal surface,
although [3H]ADP and [3H]adenosine concentrations increased
steadily, [3H]ADP remained the major reaction product
throughout the experiment. These results suggest that local
ATP release and metabolism are responsible for the distinct
nucleotide/nucleoside composition of human airway epithelial
surfaces.
Further examination of the time course experiments re-
vealed an additional discrepancy between mucosal and serosal
nucleotide metabolism with respect to adenosine production.
On the mucosal surface, reactions initiated with 0.1 mM
[3H]AMP generated higher adenosine levels than with [3H]ATP
or [3H]ADP as substrate (Fig. 3). These data are consistent
with our recent finding that ATP and ADP are competitive
inhibitors of mucosal ectoAMPase activities on human airway
epithelia (34). In contrast, ATP and ADP did not interfere with
adenosine production on the serosal surface. Collectively, the
above experiments clearly demonstrate that in human airways,
mucosal and serosal epithelial surfaces constitute separate and
distinct compartments for nucleotide metabolism.
Cell-associated and Secreted Ectonucleotidases—These ex-
periments were designed to determine whether extracellular
nucleotide metabolism on human airway epithelial surfaces
results from the activities of cell-associated or soluble ecto-
FIG. 1. Mucosal and serosal epithelial surfaces are separate
compartments. Primary bronchial cultures were incubated in 0.35 ml
of bilateral KRB (pH 7.4) containing mucosal (A) or serosal (B) 0.1 mM
[3H]ADP (0.5 Ci). Buffer samples were collected from both sides over
60 min and analyzed by HPLC. A and B, mucosal and serosal [3H]ADP
were converted into [3H]ATP, [3H]AMP, [3H]adenosine (ADO), and
[3H]inosine (INO). No radiolabeled compound except hypoxanthine
(HP) crossed the epithelial layer. HPLC traces are typical results from
four experiments. The [3H] designation was omitted for clarity.
FIG. 2. Nucleotide metabolism on human airway epithelia. Pri-
mary bronchial cultures incubated in 0.35 ml of bilateral KRB (pH 7.4)
and assayed on the mucosal surface with 0.1 mM [3H]ATP (0.5 Ci)
or 0.1 mM [3H]UTP (0.5 Ci), without (A) or with (B) nucleoside
transporter inhibitors (2 mM phloridzin  0.1 mM dipyridamole). A,
mucosal KRB samples collected over 5 min and analyzed by HPLC
showed sequential dephosphorylation of [3H]ATP into [3H]ADP,
[3H]AMP, and [3H]adenosine (ADO) and of [3H]UTP into [3H]UDP,
[3H]UMP, and [3H]uridine (URI). B, transporter blockers enhanced
inosine (INO) and hypoxanthine (HP) production. HPLC traces are
typical results from six experiments. The [3H] designation was omitted
for clarity.
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nucleotidases. Because all enzymatic assays conducted on the
epithelial cultures involved a 30-min preincubation followed by
a 30- to 40-min incubation period, enzyme release was assessed
in KRB collected after a 0–60-min conditioning period on a
mucosal or serosal surface (see “Experimental Procedures”).
Primary cultures of bronchial epithelial cells were assayed for
total and released activities with 1 mM ATP (Fig. 4A). On the
mucosal surface, ectoATPase activity released in conditioned
KRB increased with exposure time and represented 8% of
total surface activity after 60 min. The enzyme fraction remain-
ing on the epithelial surface after conditioned KRB was col-
lected could not be removed by excessive wash (five times) with
PBS. On the serosal surface, no significant enzyme activity was
detected in conditioned KRB over 60 min. These results suggest
that the enzymes supporting nucleotide metabolism on human
airway epithelia are cell-associated ectonucleotidases.
Impact of PCL Volume on ATP Metabolism—The biochemi-
cal characterization of extracellular nucleotide metabolism on
the epithelial cultures required an artificially large liquid vol-
ume (350 l). Indeed, the mucosal surface of human airway
epithelia in culture is covered by a thin PCL layer of 5–10 m
in height (4), corresponding to an average volume of 10 l over
a 1-cm2 Transwell. To test the impact of PCL volume on nucle-
otide metabolism, the mucosal surface of bronchial epithelial
cultures was assayed with 0.1 mM [3H]ATP in 0, 0.2, or 0.35 ml
of KRB (see “Experimental Procedures”). The assays conducted
in the absence of KRB also documented for the first time the in
vivo properties of ATP metabolism within the PCL layer. Fig.
4B shows that the half-life (t1⁄2) of [
3H]ATP increased with the
PCL volume. In the absence of KRB, [3H]ATP concentration
was reduced below 1 M within 1 min (t1⁄2  20 s). These
experiments clearly demonstrate that ectonucleotidases are
remarkably efficient in eliminating micromolar concentrations
of P2 receptor agonists within the PCL layer.
Distribution of Ectonucleotidases in Human Airways—The
distribution and polarity of ectonucleotidase activities in prox-
imal airways was examined with primary cultures of human
nasal and bronchial epithelial cells. Fig. 4C shows that both
cell types displayed bilateral ectonucleotidase activities toward
P2 receptor agonists (1 mM; ATP  UTP  ADP  UDP).
However, all reaction rates were 3- to 5-fold higher on mucosal
than on serosal surfaces. On the mucosal surface, bronchial
cultures hydrolyzed all four nucleotides at significantly higher
rates than nasal cultures. Interestingly, no significant differ-
ence in metabolic rates was noted between the two cell types on
the serosal surface.
Because distal airways constitute the main target for aero-
solized treatments of chronic obstructive lung diseases (43), we
tested their ability to eliminate therapeutic concentrations of
P2 receptor agonists. Because of the limited availability of
bronchiolar epithelial cells, we tested the possibility of using P1
cultures. Fig. 5A shows that primary and P1 bronchial cultures
preserved the in vivo morphologic characteristics of bronchial
epithelia, with columnar ciliated and secretory cells facing the
mucosal surface (38). These cultures were assayed with bilat-
eral 1 mM ATP or ADP. Although mucosal metabolism occurred
at a significantly lower rate on P1 than on primary cultures,
the ATP/ADP hydrolysis ratio was preserved through passage
(Fig. 5B). Therefore, P1 cultures were used to investigate the
relationship between airway generation and cell surface nucle-
otide metabolism. Fig. 5C indicates that mucosal epithelial
surfaces hydrolyzed ATP and ADP with the efficiency order:
nasal  bronchial  bronchiolar cells. In contrast, there was
no significant difference between serosal activities on the three
culture types. Collectively, these experiments demonstrate
that the capacity of airway mucosa to eliminate P2 receptor
agonists increases significantly toward areas most susceptible
to airway obstruction.
Metabolism of P2 Receptor Agonists in MCC-deficient
Lungs—We tested the impact of chronic airway obstruction on
the regulation of nucleotide-mediated MCC. Primary cultures
of bronchial epithelial cells from healthy donors and CF pa-
FIG. 3. Polarity of nucleotide metabolism on human airway
epithelial surfaces. Primary cultures were incubated in 0.35 ml of
lateral KRB (pH 7.4) containing mucosal or serosal 0.1 mM [3H]ATP (0.5
Ci), [3H]ADP (0.5 Ci), or [3H]AMP (0.5 Ci). The major product of
ATP metabolism was adenosine and ADP on mucosal and serosal sur-
faces, respectively. ATP and ADP inhibited adenosine production on the
mucosal (not serosal) surface. [3H]ATP (), [3H]ADP (f), [3H]AMP (Œ),
[3H]adenosine (), and [3H]inosine (). The data are mean results from
five experiments (S.E. 10% of the mean). The [3H] designation was
omitted for consistency.
FIG. 4. Human airway ectonucleotidases are cell-associated
and predominantly mucosal. A, cell-associated ectoATPases. KRB
buffer (pH 7.4; 0.35 ml) conditioned for 0, 30, or 60 min on mucosal
(filled bars) or serosal (open bars) epithelial surfaces was collected and
assayed for released activity with 1 mM ATP. Mucosal and serosal
surfaces were assayed after 24 h for total activity. Values were calcu-
lated from linear rates of substrate decay determined by HPLC. B,
impact of liquid height on ectoATPase activity. Mucosal surface assayed
with 0.1 mM [3H]ATP in 0 (Œ), 0.2 (f), or 0.35 ml () KRB. EctoATPase
activity is inversely related to PCL volume. C, polarity of nucleotide
metabolism. Bronchial (filled bars) and nasal (open bars) cultures in-
cubated in bilateral 0.35 ml of KRB with 1 mM ATP, UTP, ADP, or UDP.
Hydrolysis rates were higher on mucosal than serosal surfaces and
higher on bronchial than nasal cultures. Values are mean 	 S.E. of 3–8
experiments (*, p  0.05. **, p  0.01).
Nucleotide Metabolism in Human Airways 20237
tients were assayed with 1 mM ATP, UTP, ADP, or UDP on the
mucosal surface. Fig. 6A shows that CF epithelia hydrolyzed all
nucleotides at significantly higher rates than normal cultures
while maintaining a normal rank order of efficiency: ATP 
UTP  ADP  UDP. Similar results were obtained with ATP
on the mucosal surface of nasal cultures (Fig. 6B). Interest-
ingly, the impact of CF on nucleotide metabolism was re-
stricted to the mucosal surface of nasal and bronchial epithelia
(Fig. 6B). These results support a widespread and polarized
up-regulation of nucleotide metabolism throughout the airways
of CF patients.
Time course experiments were performed to determine the
impact of CF on the metabolism of an airway ATP concentra-
tion generated locally from mechanical stimulation (44–46).
Normal and CF cultures of bronchial epithelial cells were mon-
itored by HPLC over 60 min after the addition of 0.01 mM
[3H]ATP to the mucosal surface. On normal cultures, this nu-
cleotide concentration produced a metabolic pattern (Fig. 6C)
similar to that of 0.1 mM ATP (Fig. 3), characterized by tran-
sient ADP and AMP accumulations and a gradual increase in
adenosine concentration. In contrast, the CF cultures gener-
ated higher rates of ATP decay and transiently enhanced ADP
accumulation and 2-fold higher rates of adenosine production
(Fig. 6D). These experiments demonstrate that CF enhances all
enzymatic reactions involved in the stepwise conversion of
mucosal ATP to adenosine.
Other chronic obstructive lung diseases affect the regulation
of P2 receptor agonists in human airways. Fig. 7A shows that
bronchial cultures from PCD, CF, and AT patients eliminated
mucosal 1 mM ATP at 2–4-fold higher rates than cultures from
healthy donors. Furthermore, as observed with CF cultures, no
significant difference in ectoATPase activity was detected on
the serosal surface between normal, PCD, and AT epithelial
cultures. To identify the ectonucleotidase(s) up-regulated in
these diseases, the mucosal assays were repeated with 1 mM
ATP in the presence 10 mM levamisole, a specific inhibitor of
NS AP (34). Expressed exclusively on the mucosal surface of
human airway epithelia, this ectonucleotidase dephosphory-
lates ATP into ADP, AMP, and adenosine (34). We show that
NS AP activity (Fig. 7A) and mRNA expression (Fig. 7B) were
3–6-fold higher in cultures from PCD, CF, and AT patients
than from healthy donors. Taken together, these data suggest
that chronic airway obstruction accelerates the removal of
aerosolized P2 receptor agonists, mainly through an up-regu-
lation of NS AP.
FIG. 7. Airway nucleotide clearance is enhanced by NS AP in
chronic lung diseases. A, acceleration of nucleotide clearance. Bron-
chial cultures of epithelial cells from healthy donors (N) or patients with
PCD, CF, or AT assayed in bilateral 0.35 ml of KRB (pH 7.4) with
bilateral 1 mM ATP (filled bars) or 1 mM ATP  10 mM levamisole (NS
AP inhibitor; open bars). Hydrolytic rates calculated from linear decay
in substrate concentrations determined by HPLC. Values are mean 	
S.E. of five experiments (*, p  0.05). B, up-regulation of NS AP
expression. RNase protection assays conducted on the epithelial cul-
tures assayed in panel A. Values, normalized with -actin, represent
mean 	 S.E. of three-five experiments (*, p  0.05).
FIG. 5. Increasing efficiency of nucleotide metabolism with
airway generation. A, typical brightfield hematoxylin and eosin
staining sections of main bronchial tissue and primary and P1 cultures.
B, impact of passage. Primary or P1 bronchial cultures assayed in
bilateral 0.35 ml of KRB (pH 7.4) with 1 mM ATP (filled bars) or ADP
(open bars). The ATPase/ADPase activity ratio was preserved by pas-
sage. C, widespread distribution of nucleotide metabolism. P1 cultures
of human nasal (filled), bronchial (gray), or bronchiolar (open) epithelial
cells assayed in bilateral 0.35 ml of KRB with 1 mM ATP or ADP.
Hydrolysis rates calculated from linear rates of substrate decay were
determined by HPLC. Values are mean 	 S.E. of four experiments *, p
 0.05. **, p  0.01.
FIG. 6. Cystic fibrosis up-regulates nucleotide metabolism in
human airways. A, enhanced clearance of P2 receptor agonists. Nor-
mal (filled bars) and CF (open bars) bronchial cultures assayed in
bilateral 0.35 ml of KRB (pH 7.4) with mucosal 1 mM ATP, UTP, ADP,
or UDP. B, CF effects confined to the mucosal surface. Nasal and
bronchial cultures from healthy donors (filled bars) and CF patients
(open bars) assayed with bilateral 1 mM ATP as in panel A. Hydrolysis
rates calculated from linear rates of substrate decay determined by
HPLC. Values are mean 	 S.E. of nine experiments (*, p  0.05). C–D,
impact of CF on the metabolic patterns. Bronchial cultures from
healthy donors (C) and CF (D) patients assayed with mucosal 0.01 mM
[3H]ATP as in panel A. CF enhances ADP and adenosine accumulation.
[3H]ATP (), [3H]ADP (f), [3H]AMP (Œ), [3H]adenosine (), and [3H]i-
nosine (). Mean results from five experiments (S.E. 10% of the
mean).
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DISCUSSION
Clinical studies have shown that aerosolized UTP temporar-
ily relieves CF patients from chronic airway obstruction (1 h)
(30–32). We tested the hypothesis that the duration of nucle-
otide-mediated MCC is limited by the rapid clearance of P2
receptor agonists from airway epithelial surfaces. Aerosolized
nucleotides could be eliminated by paracellular permeation
through the epithelial barrier and/or by surface metabolism. In
the present study, we clearly showed that therapeutic concen-
trations (0.1–1.0 mM) (30) of [3H]ADP are unable to cross the
epithelial layer in either direction. In addition, primary cul-
tures of human airway epithelia were impermeable to mucosal
0.1 mM [3H]ATP (34). These results indicate that P2 receptor
agonists are not eliminated from human airways by perme-
ation through the epithelium.
The observation that several radiolabeled species accumu-
lated following the addition of [3H]ADP suggested the presence
of metabolic activities on human airway epithelial surfaces. We
reported earlier that mucosal [32P]ATP levels on primary
cultures of human nasal epithelial cells are maintained by a
balance between basal release and surface metabolism, de-
tected by the production of radiolabeled inorganic phosphate
(32P) (15). Unfortunately, the non-radioactive products of
[32P]ATP metabolism were not identified by UV detection. In
the present study, a thorough investigation of extracellular
nucleotide metabolism was conducted by time course experi-
ments monitoring the buffer composition in tritiated com-
pounds following the addition of 0.1 mM [3H]ATP or [3H]UTP to
the mucosal surface. The radioisotope is positioned on the base,
which is carried by all nucleotides and nucleosides generated
from the metabolism of these substrates. We showed that
[3H]ATP is gradually replaced by [3H]ADP, followed by
[3H]AMP and finally [3H]adenosine. Similar results were ob-
tained with [3H]UTP. The directionality of nucleotide metabo-
lism was confirmed with [3H]ADP as substrate, which was
dephosphorylated into [3H]AMP, followed by [3H]adenosine.
The metabolism of [3H]ADP also generated small amounts of
[3H]ATP, most likely by the ectoadenylate kinase activity
(2ADP 7 ATP  AMP) recently identified at the surface of
human nasal and bronchial epithelial cells (47, 48). Finally,
assays initiated with [3H]AMP generated [3H]adenosine. Col-
lectively, these experiments demonstrate that P2 receptor ago-
nists (ATP, UTP, ADP, and UDP) are eliminated from human
airway epithelial surfaces by sequential dephosphorylation.
Dephosphorylating ectonucleotidases have been reported in
several human tissues, either as soluble or cell-associated pro-
teins (33). We evaluated the physiological importance of airway
ectonucleotidases by addressing their localization, polarity,
and biochemical properties. Our data indicate that ATP metab-
olism is conducted primarily (90%) by cell-associated ecto-
nucleotidases on both epithelial surfaces. Similar findings were
reported for AMP dephosphorylation by NS AP and ecto 5-
nucleotidase (34), and for ectoadenylate kinase activity (47, 48)
on primary cultures of human airway epithelial cells. These
data suggest that extracellular nucleotide metabolism could
locally limit the duration of P2 receptor activation.
Mucociliary clearance in human airways is acutely stimu-
lated by respiratory irritants (49). Mechanical stress, induced
by physical interaction of an air contaminant or a microbe with
the epithelium, causes a local burst of ATP release (11, 16–18),
which then stimulates P2 receptor-mediated MCC (9). Because
P2 receptors desensitize in response to sustained activation
(50, 51), the ability of the epithelium to detect the next threat
may depend on the time required to restore basal ATP level.
Incidentally, we showed that high ATP concentrations (0.1 mM)
are eliminated in less than a minute (t1⁄2 
 20 s) within in vivo
PCL volume. Such remarkable efficiency supports a pivotal role
for ectonucleotidases in the maintenance of alertness of air-
ways against infectious particles.
Two essential components of nucleotide-mediated MCC were
reported to exhibit a bilateral distribution on human airway
epithelial surfaces: ATP release (9) and P2 receptors (9, 12).
Evidence presented here demonstrates that ectonucleotidases
adopt a similar distribution, with 3- to 5-fold higher efficiency
on the mucosal surface. Comparative analysis of the time
course experiments revealed surface-specific patterns of ecto-
nucleotidase activities. On the mucosal surface, ATP metabo-
lism was characterized by the transient accumulation of ADP
and AMP, followed by the sustained accumulation of adeno-
sine. Conversely, the serosal surface produced mainly ADP
from ATP throughout the experiment. The fact that the major
reaction product generated from ATP metabolism on mucosal
(adenosine) and serosal (ADP) surfaces corresponds to the most
abundant purine measured under resting conditions (42) sup-
ports an intimate relationship between ATP release, ectonucle-
otidase activities, and P2 receptor-mediated MCC. For in-
stance, we showed that the mucosal surface generates higher
rates of adenosine production from AMP than from ADP or
ATP as substrate. Extracellular ATP and ADP were identified
as competitive inhibitors of AMP metabolism on various cell
types (52, 53), including the mucosal surface of human airway
epithelia (34). This regulatory mechanism suggests that ATP
release could temporarily delay the transition between P2
(ATP, ADP) and P1 (adenosine) receptor-mediated events in
human airways.
Given the potential importance of ectonucleotidases in the
regulation of nucleotide-mediated MCC, their activities should
be particularly critical in small airways, which are most sus-
ceptible to obstruction (43). The present study demonstrates,
for the first time, that extracellular nucleotide metabolism
extends below the tracheobronchial tree. Furthermore,
comparative analysis indicated that the rates of ATP and
ADP hydrolysis increase considerably toward alveoli
(nose  bronchi  bronchioles). In contrast, serosal ectonucleo-
tidase activities were not influenced by airway generation.
Recent studies suggest that the remarkable efficiency of bron-
chiolar epithelia may represent an adaptative response to more
frequent ATP outbursts, triggered by particle deposition and
bronchoconstriction-mediated membrane stretch (54). Mechan-
ical stimulation of cultured human airway epithelial cells
(Calu-3) induced ATP release from the mucosal surface, with
negligible nucleotide release from the serosal surface.2 Wiendl
et al. (55) showed that repetitive exposures of a human epider-
mal cell line (A431) to an ATP concentration (70 M) detected in
proximity to a site of stimulated release (44–46) up-regulated
all ectonucleotidase activities supporting the conversion of ATP
to adenosine. Collectively, these studies suggest that, in human
airways, mucosal nucleotide metabolism may be attuned to the
intensity of mechanically induced ATP release and P2 receptor-
mediated MCC.
The relationship between nucleotide metabolism and P2 re-
ceptor-mediated MCC hypothesized above for healthy lungs
would predict lower ectonucleotidase activities for the muco-
static airways of CF patients. However, we provide evidence
that CF accelerates nucleotide metabolism in human airways.
On the mucosal surface of nasal and bronchial epithelial cul-
tures, CF increased by 2–4-fold the hydrolysis rate of P2 re-
ceptor agonists (ATP, UTP, ADP, and UDP). Alternatively, the
impact of CF on mucosal nucleotide metabolism could provide
protection against ATP-mediated epithelial damage. The lungs
2 E. R. Lazarowski, personal communication.
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of CF patients may be exposed locally to unusually elevated
concentrations of ATP, released from damaged epithelia, lysed
bacteria, and activated leukocytes. Although not reported in
normal airway epithelia, P2X7 receptors were detected by RT-
PCR in primary epithelial cultures from CF nasal polyps and in
CF lung epithelial cell lines (12). These channels are well
known to induce cell death upon activation by ATP concentra-
tions (EC50:0.1–1 mM) that may be reached locally on CF air-
way epithelia (56). These findings suggest that ectonucleoti-
dase activities may not be regulated by nucleotide-mediated
MCC but rather by mucosal ATP release.
An indirect consequence of accelerated nucleotide metabo-
lism on the mucosal surface of CF airway epithelia is the
enhanced production of the P1 receptor agonist, adenosine.
Time course experiments indicated that CF up-regulates by
3-fold all reactions supporting the conversion of mucosal ATP
to adenosine. Furthermore, mucosal adenosine levels reached
2-fold higher values on CF cultures. Excess adenosine is not
expected to improve MCC in CF lungs because A2B receptor-
mediated stimulation of CFTR channel activity is defective
(57). However, chronically elevated adenosine induced airway
inflammation in mice (58). These results suggest that enhanced
mucosal ATP metabolism and adenosine production may exac-
erbate chronic inflammation in the lungs of CF patients.
A key finding in this work is the widespread occurrence of
enhanced nucleotide metabolism on airway epithelial surfaces
from patients diagnosed with chronic obstructive lung diseases.
We showed that primary cultures of bronchial epithelial cells
from patients with PCD, CF, or AT displayed 2–4-fold higher
rates of mucosal ATP hydrolysis than normal epithelia. There-
fore, these diseases may share factors regulating airway ecto-
nucleotidases. Chronic airway obstruction is commonly associ-
ated with recurrent cycles of inflammatory responses to
bacterial infection (5). Besides the excessive ATP released un-
der these conditions, inflammatory mediators may also regu-
late mucosal nucleotide metabolism. The pro-inflammatory cy-
tokine, interleukin-1, increased by 6-fold the mRNA
expression of NS AP in primary cultures of human bronchial
epithelial cells (34). In the present work, we showed that NS
AP expression and mucosal activity were up-regulated 3–6-fold
by PCD, CF, or AT. Furthermore, NS AP activity among the
different diseases followed the same rank order of efficiency as
total ectoATPase activity (PCD  CF  AT). Collectively,
these data support a major role for NS AP in the up-regulation
of nucleotide clearance in chronic obstructive lung diseases.
In summary, the present study demonstrates that P2 recep-
tor agonists are rapidly eliminated from human airway epithe-
lial surfaces. We provide evidence that nucleotide clearance
does not involve permeation through the epithelial layer but
rather extracellular metabolism by cell-associated enzymes.
These ectonucleotidases display significantly higher activities
on mucosal epithelial surfaces, with increasing efficiency to-
ward areas most susceptible to airway obstruction. The rapid
clearance of micromolar ATP concentrations may prevent P2
receptor desensitization (50, 51), thereby maintaining ade-
quate nucleotide-mediated MCC of inhaled infectious particles.
In chronic obstructive lung diseases, enhanced nucleotide me-
tabolism could represent a defense mechanism against the
deleterious effects of excess ATP (56). Finally, we identified NS
AP as the major ectonucleotidase responsible for the termina-
tion of aerosolized nucleotide-mediated MCC in the lungs of CF
patients.
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